The lawsuit, filed in the District of New Jersey as Mazzarino v. ADMA Biologics, Inc., claims the biopharmaceutical firm misled the market regarding its financial health and internal controls. Plaintiffs contend the company inflated revenue through channel stuffing and failed to disclose critical relationships with distributors. These allegations gained traction after a March 2026 report from Culper Research, which argued that the company’s reported growth was largely a fabrication driven by extended payment terms and accounting maneuvers.

Market reaction to these disclosures was immediate and severe. ADMA Biologics shares dropped over 16% following the initial report. While the company issued a statement labeling the findings as speculative and inaccurate, investor confidence further eroded when Cantor Fitzgerald downgraded the stock from Overweight to Neutral. That subsequent move triggered an additional decline of more than 13%. Robbins Geller Rudman & Dowd LLP, the firm representing the plaintiffs, is now coordinating the process for investors to serve as lead representatives, a role that involves directing the litigation on behalf of the broader class.